These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10337991)

  • 1. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.
    Ramus SJ; Bobrow LG; Pharoah PD; Finnigan DS; Fishman A; Altaras M; Harrington PA; Gayther SA; Ponder BA; Friedman LS
    Genes Chromosomes Cancer; 1999 Jun; 25(2):91-6. PubMed ID: 10337991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
    Crook T; Brooks LA; Crossland S; Osin P; Barker KT; Waller J; Philp E; Smith PD; Yulug I; Peto J; Parker G; Allday MJ; Crompton MR; Gusterson BA
    Oncogene; 1998 Oct; 17(13):1681-9. PubMed ID: 9796697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
    Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
    J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
    Schuyer M; Berns EM
    Mol Cell Endocrinol; 1999 Sep; 155(1-2):143-52. PubMed ID: 10580847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
    Rhei E; Bogomolniy F; Federici MG; Maresco DL; Offit K; Robson ME; Saigo PE; Boyd J
    Cancer Res; 1998 Aug; 58(15):3193-6. PubMed ID: 9699640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
    Smith PD; Crossland S; Parker G; Osin P; Brooks L; Waller J; Philp E; Crompton MR; Gusterson BA; Allday MJ; Crook T
    Oncogene; 1999 Apr; 18(15):2451-9. PubMed ID: 10229196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations.
    Khoo US; Ngan HY; Cheung AN; Chan KY; Lu J; Chan VW; Lau S; Andrulis IL; Ozcelik H
    Hum Mutat; 2000 Jul; 16(1):88-9. PubMed ID: 10874312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
    Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
    Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
    Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
    Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
    Staff S; Nupponen NN; Borg A; Isola JJ; Tanner MM
    Genes Chromosomes Cancer; 2000 Aug; 28(4):432-42. PubMed ID: 10862052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
    van Der Looij M; Wysocka B; Brozek I; Jassem J; Limon J; Olah E
    Hum Mutat; 2000 May; 15(5):480-1. PubMed ID: 10790213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
    Claes K; Machackova E; De Vos M; Mortier G; De Paepe A; Messiaen L
    Hum Mutat; 1999; 13(3):256. PubMed ID: 10090482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Brca1 and Brca2 proteins and tumor pathogenesis.
    Ingvarsson S
    Anticancer Res; 1999; 19(4B):2853-61. PubMed ID: 10652564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
    Reedy MB; Hang T; Gallion H; Arnold S; Smith SA
    Gynecol Oncol; 2001 Jun; 81(3):441-6. PubMed ID: 11371136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA2 mutations in primary breast and ovarian cancers.
    Lancaster JM; Wooster R; Mangion J; Phelan CM; Cochran C; Gumbs C; Seal S; Barfoot R; Collins N; Bignell G; Patel S; Hamoudi R; Larsson C; Wiseman RW; Berchuck A; Iglehart JD; Marks JR; Ashworth A; Stratton MR; Futreal PA
    Nat Genet; 1996 Jun; 13(2):238-40. PubMed ID: 8640235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.
    Welcsh PL; King MC
    Hum Mol Genet; 2001 Apr; 10(7):705-13. PubMed ID: 11257103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
    Van Der Looij M; Szabo C; Besznyak I; Liszka G; Csokay B; Pulay T; Toth J; Devilee P; King MC; Olah E
    Int J Cancer; 2000 Jun; 86(5):737-40. PubMed ID: 10797299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.
    Grzybowska E; Zientek H; Jasinska A; Rusin M; Kozlowski P; Sobczak K; Sikorska A; Kwiatkowska E; Gorniak L; Kalinowska E; Utracka-Hutka B; Wloch J; Chmielik E; Krzyzosiak WJ
    Hum Mutat; 2000 Dec; 16(6):482-90. PubMed ID: 11102977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.